Henry Schein announced the appointment of Frederick M. Lowery as Chief Executive Officer effective March 2, 2026, succeeding Stanley M. Bergman, who led the company for 35 years and will remain as Chairman of the Board. The transition follows a six-month succession process overseen by the Nominating and Governance Committee, which evaluated both internal and external candidates and received over 50 expressions of interest from leading healthcare executives. Management emphasized that Mr. Lowery’s arrival aligns with the next phase of the company’s BOLD+1 strategic plan, targeting annual organic revenue growth of 5% to 7% and operating margin expansion of 50 basis points per year over the next three years.

Mr. Lowery brings more than two decades of healthcare leadership, most recently serving as Executive Vice President and President of Laboratory Products and BioProduction at Thermo Fisher Scientific, where he delivered above-market revenue growth of 10% annually and improved segment operating profit margin by 200 basis points. His experience in distribution, manufacturing, R&D and go-to-market execution is expected to bolster Henry Schein’s initiatives in digital technology integration, private-label product expansion and supply-chain optimization. During the presentation at the J.P. Morgan Healthcare Conference, Mr. Lowery highlighted plans to invest $150 million in technology platforms over the next two years and to accelerate the rollout of the company’s cloud-based practice management system to 20,000 offices globally.

Phil Laskawy, Lead Director and Chair of the Nominating and Governance Committee, underscored that the board conducted an extensive external search and that Mr. Lowery’s operational track record and leadership philosophy best position Henry Schein for sustained value creation. The board cited strong alignment with private-equity partner KKR, which holds approximately 14% of shares, as a factor in supporting a CEO who can drive both innovation and margin improvement. Investors will monitor the impact of the leadership change on organic growth metrics, free cash flow generation—targeted at $750 million for fiscal 2026—and potential share repurchase authorizations under the company’s capital allocation framework.